loading
Crispr Therapeutics Ag stock is traded at $54.32, with a volume of 1.72M. It is up +2.84% in the last 24 hours and down -17.61% over the past month. Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
See More
Previous Close:
$52.82
Open:
$52.81
24h Volume:
1.72M
Relative Volume:
0.54
Market Cap:
$4.94B
Revenue:
$170.10M
Net Income/Loss:
$-239.59M
P/E Ratio:
-19.40
EPS:
-2.8
Net Cash Flow:
$-191.20M
1W Performance:
-9.06%
1M Performance:
-17.61%
6M Performance:
+13.38%
1Y Performance:
+14.36%
1-Day Range:
Value
$52.60
$55.08
1-Week Range:
Value
$51.80
$59.46
52-Week Range:
Value
$30.04
$71.13

Crispr Therapeutics Ag Stock (CRSP) Company Profile

Name
Name
Crispr Therapeutics Ag
Name
Phone
(617) 315-4600
Name
Address
BAARERSTRASSE 14, ZUG
Name
Employee
393
Name
Twitter
@crisprtx
Name
Next Earnings Date
2024-12-05
Name
Latest SEC Filings
Name
CRSP's Discussions on Twitter

Compare CRSP with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CRSP
Crispr Therapeutics Ag
54.32 5.24B 170.10M -239.59M -191.20M -2.80
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-14-25 Upgrade Evercore ISI In-line → Outperform
Feb-12-25 Upgrade TD Cowen Sell → Hold
Feb-03-25 Initiated H.C. Wainwright Buy
Aug-06-24 Reiterated Needham Buy
Aug-02-24 Initiated Rodman & Renshaw Buy
Jun-28-24 Resumed Guggenheim Neutral
Feb-15-24 Initiated Wolfe Research Peer Perform
Dec-11-23 Downgrade TD Cowen Market Perform → Underperform
Oct-17-23 Downgrade Cantor Fitzgerald Overweight → Neutral
Sep-27-23 Initiated Mizuho Buy
Aug-17-23 Upgrade Citigroup Neutral → Buy
May-30-23 Initiated William Blair Outperform
Apr-13-23 Initiated Cantor Fitzgerald Overweight
Mar-21-23 Initiated Bernstein Mkt Perform
Mar-17-23 Initiated Bryan Garnier Buy
Mar-07-23 Initiated Robert W. Baird Neutral
Oct-11-22 Initiated Morgan Stanley Underweight
Aug-09-22 Downgrade Barclays Overweight → Equal Weight
Jun-23-22 Downgrade Evercore ISI Outperform → In-line
Jun-17-22 Initiated BMO Capital Markets Outperform
Apr-28-22 Initiated Credit Suisse Neutral
Dec-07-21 Initiated Cowen Market Perform
Oct-19-21 Initiated SVB Leerink Outperform
Jun-14-21 Upgrade Citigroup Sell → Neutral
Apr-21-21 Upgrade Jefferies Hold → Buy
Mar-04-21 Initiated JMP Securities Mkt Outperform
Dec-10-20 Reiterated Chardan Capital Markets Buy
Dec-10-20 Downgrade Jefferies Buy → Hold
Dec-10-20 Reiterated Needham Buy
Dec-07-20 Downgrade Wells Fargo Overweight → Equal Weight
Oct-23-20 Initiated RBC Capital Mkts Sector Perform
Oct-05-20 Initiated BofA Securities Buy
Jul-28-20 Reiterated Needham Buy
Jul-14-20 Initiated SunTrust Buy
Jun-15-20 Reiterated Canaccord Genuity Buy
Mar-05-20 Initiated Stifel Hold
Feb-03-20 Downgrade Evercore ISI Outperform → In-line
Nov-19-19 Upgrade William Blair Mkt Perform → Outperform
Nov-12-19 Upgrade Oppenheimer Perform → Outperform
Aug-01-19 Initiated Jefferies Buy
Jul-26-19 Initiated Canaccord Genuity Buy
Jun-10-19 Initiated ROTH Capital Buy
Apr-12-19 Initiated Evercore ISI Outperform
Mar-14-19 Initiated William Blair Mkt Perform
Jan-28-19 Downgrade Goldman Buy → Neutral
Jan-22-19 Downgrade Citigroup Neutral → Sell
View All

Crispr Therapeutics Ag Stock (CRSP) Latest News

pulisher
Aug 20, 2025

Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know - MSN

Aug 20, 2025
pulisher
Aug 20, 2025

Watch for Trend Continuation in CRISPR Therapeutics AG Next WeekJuly 2025 Rallies & Free AI Powered Buy and Sell Recommendations - thegnnews.com

Aug 20, 2025
pulisher
Aug 20, 2025

Vestmark Advisory Solutions Inc. Sells 18,728 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat

Aug 20, 2025
pulisher
Aug 19, 2025

Bernstein Remains a Hold on Crispr Therapeutics AG (CRSP) - The Globe and Mail

Aug 19, 2025
pulisher
Aug 19, 2025

Fox Run Management L.L.C. Acquires New Stake in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

Aug 19, 2025
pulisher
Aug 18, 2025

CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for Investors - MSN

Aug 18, 2025
pulisher
Aug 18, 2025

What Makes Crispr Therapeutics Ag (CRSP) a Good Buy? - Yahoo Finance

Aug 18, 2025
pulisher
Aug 18, 2025

EverSource Wealth Advisors LLC Purchases 84,708 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat

Aug 18, 2025
pulisher
Aug 18, 2025

CRISPR-based therapies signal a new direction in tackling infectious diseases - Clinical Trials Arena

Aug 18, 2025
pulisher
Aug 18, 2025

CRISPR Therapeutics AG Shows Support at Fibonacci Level2025 Key Highlights & Expert-Curated Trade Recommendations - sundaytimes.kr

Aug 18, 2025
pulisher
Aug 17, 2025

Virtu Financial LLC Purchases New Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

Aug 17, 2025
pulisher
Aug 17, 2025

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates - MSN

Aug 17, 2025
pulisher
Aug 17, 2025

Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns - Yahoo Finance

Aug 17, 2025
pulisher
Aug 16, 2025

Benjamin Edwards Inc. Purchases 5,853 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

Aug 16, 2025
pulisher
Aug 16, 2025

Pattern Scan Adds CRISPR Therapeutics AG to WatchlistPrice Action & Weekly Breakout Stock Alerts - kangso.co.kr

Aug 16, 2025
pulisher
Aug 16, 2025

Crispr Therapeutics AG: Stock Surge Amid Clinical Advances - TipRanks

Aug 16, 2025
pulisher
Aug 16, 2025

Is CRISPR Therapeutics' (CRSP) Rising Net Loss a Sign of Bold Investment or Growing Pressure? - Yahoo Finance

Aug 16, 2025
pulisher
Aug 15, 2025

Crispr Therapeutics shares rise 1.48% premarket after ReproCELL Incorporated receives ¥5.3 million in funding. - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Equities Analysts Offer Predictions for CRSP Q4 Earnings - MarketBeat

Aug 15, 2025
pulisher
Aug 14, 2025

CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Aug 14, 2025
pulisher
Aug 14, 2025

Crispr Therapeutics shares rise 3.12% intraday after Allogene Therapeutics' positive trial updates. - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Upgrading Crispr Therapeutics To Hold Ahead Of A Catalyst-Rich 2H 2025 - Seeking Alpha

Aug 14, 2025
pulisher
Aug 14, 2025

Blair William & Co. IL Cuts Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

Aug 14, 2025
pulisher
Aug 13, 2025

CRISPR Therapeutics Bets Big On Gene-Editing Breakthroughs - Finimize

Aug 13, 2025
pulisher
Aug 13, 2025

CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by Cetera Investment Advisers - MarketBeat

Aug 13, 2025
pulisher
Aug 13, 2025

Crispr Therapeutics Faces Stock Dip Amid Promising Developments - MSN

Aug 13, 2025
pulisher
Aug 13, 2025

Crispr Therapeutics shares rise 1.10% premarket after Metagenomi reported positive business updates and financial results. - AInvest

Aug 13, 2025
pulisher
Aug 12, 2025

Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings? - Yahoo Finance

Aug 12, 2025
pulisher
Aug 12, 2025

Chardan Capital Has Strong Estimate for CRSP FY2026 Earnings - MarketBeat

Aug 12, 2025
pulisher
Aug 12, 2025

Westwood Holdings Group Inc. Reduces Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

Aug 12, 2025
pulisher
Aug 11, 2025

Research Analysts Issue Forecasts for CRSP FY2025 Earnings - MarketBeat

Aug 11, 2025
pulisher
Aug 11, 2025

3 Monster Stocks in the Making to Buy Right Now - AOL.com

Aug 11, 2025
pulisher
Aug 10, 2025

Barclays Forecasts Strong Price Appreciation for CRISPR Therapeutics (NASDAQ:CRSP) Stock - MarketBeat

Aug 10, 2025
pulisher
Aug 10, 2025

CRISPR Therapeutics (NASDAQ:CRSP) Given New $80.00 Price Target at HC Wainwright - MarketBeat

Aug 10, 2025
pulisher
Aug 10, 2025

CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading - MSN

Aug 10, 2025
pulisher
Aug 10, 2025

Q3 EPS Estimate for CRISPR Therapeutics Boosted by Analyst - MarketBeat

Aug 10, 2025
pulisher
Aug 10, 2025

Leerink Partnrs Brokers Reduce Earnings Estimates for CRSP - MarketBeat

Aug 10, 2025
pulisher
Aug 09, 2025

CRISPR Therapeutics AG Insider Buying: Douglas Treco Acquires 20,000 Shares - AInvest

Aug 09, 2025
pulisher
Aug 09, 2025

CRISPR Therapeutics (NASDAQ:CRSP) Given "Buy" Rating at Chardan Capital - MarketBeat

Aug 09, 2025

Crispr Therapeutics Ag Stock (CRSP) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Crispr Therapeutics Ag Stock (CRSP) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Treco Douglas A
Director
Aug 06 '25
Buy
57.03
20,000
1,140,600
22,000
George Simeon
Director
Jul 16 '25
Buy
52.03
989,812
51,499,918
1,730,179
Patel Naimish
Chief Medical Officer
May 29 '25
Sale
35.94
3,932
141,316
6,068
Kulkarni Samarth
Chief Executive Officer
Mar 21 '25
Sale
41.23
10,031
413,578
195,085
Bruno Julianne
Chief Operating Officer
Mar 21 '25
Sale
41.23
1,714
70,668
10,544
Prasad Raju
Chief Financial Officer
Mar 21 '25
Sale
41.23
2,197
90,582
16,767
KASINGER JAMES R.
General Counsel and Secretary
Mar 21 '25
Sale
41.23
3,185
131,318
81,729
Prasad Raju
Chief Financial Officer
Mar 17 '25
Sale
41.80
3,762
157,252
12,714
Kulkarni Samarth
Chief Executive Officer
Mar 11 '25
Sale
42.42
9,973
423,055
180,890
Kulkarni Samarth
Chief Executive Officer
Mar 12 '25
Sale
43.32
4,462
193,294
185,428
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Cap:     |  Volume (24h):